Live stream preview
The proportion of patients who reach the BMD surrogate threshold effect on romosozumab a post hoc analysis of the randomised FRAME and ARCH phase 3 trials Prof Jeffrey Hassall
ANZ Bone & Mineral Society 2022 • 9m 51s
Up Next in ANZ Bone & Mineral Society 2022
-
Patients on dialysis are at lower ris...
-
Minghao Zheng Orthopaedic Innovation ...
-
Emerging approaches to investigate mu...
